Wesenhagen, Kirsten E. J.
de Leeuw, Diederick M.
Tomassen, Jori
Gobom, Johan
Bos, Isabelle
Vos, Stephanie J. B.
Martinez-Lage, Pablo
Tainta, Mikel
Popp, Julius
Peyratout, Gwendoline
Tsolaki, Magda
Vandenberghe, Rik
Freund-Levi, Yvonne
Verhey, Frans
Lovestone, Simon
Streffer, Johannes
Dobricic, Valerija
Blennow, Kaj
Scheltens, Philip
Smit, August B.
Bertram, Lars
Teunissen, Charlotte E.
Zetterberg, Henrik
Tijms, Betty M.
Visser, Pieter Jelle
,
Funding for this research was provided by:
ZonMw (733050824, 733050824, 733050824, 733050824)
Innovative Medicines Initiative (115372, 115372, 115372, 115372)
Alzheimerfonden (AF-930934)
Hjärnfonden (FO2018-0315, FO2017-0243, FO2019-0228)
Swedish Research Council (2017-00915, 2018-02532)
Alzheimer's Drug Discovery Foundation (RDAPB-201809-2016615, 201809-2016862)
Swedish Alzheimer Foundation (AF-742881)
the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (ALFGBG-715986)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236, JPND2021-00694)
National Institutes of Health (1R01AG068398-01, U01 AG024904)
Alzheimer's Association (ZEN-21-848495)
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
AD strategic Fund and Alzheimer's Association (ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C)
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (860197)
Article History
Received: 19 June 2024
Accepted: 19 February 2025
First Online: 3 March 2025
Declarations
:
: For both ADNI and EMIF-AD MBD, Local institutional review boards approved the procedures for this study and written informed consent was obtained in accordance with the Declaration of Helsinki. Supplementary Table 4 contains a full overview of Ethical Committee/IRB names of each center.
: Not applicable.
: KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. PS has acquired grants for the institution from GE Healthcare and Piramal and received consultancy/speaker fees paid to the institution from Novartis, Probiodrug, Biogen, Roche, and EIP Pharma, LLC in the past 2 years. CT received grants from the European Commission, the Dutch Research Council (ZonMW), Association of Frontotemporal Dementia/Alzheimer’s Drug Discovery Foundation, The Weston Brain Institute, Alzheimer Netherlands. Prof. dr. Teunissen has functioned in advisory boards of Roche, received non-financial support in the form of research consumables from ADxNeurosciences and Euroimmun, performed contract research or received grants from Probiodrug, Biogen, Esai, Toyama, Janssen Prevention Center, Boehringer, AxonNeurosciences, EIP farma, PeopleBio, Roche. The other authors report no conflict of interest.